Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
Novo Nordisk has unveiled an ambitious plan to drive future growth beyond its top-selling obesity drugs Wegovy and Ozempic, which face patent expirations in the early 2030s. However, investors remain skeptical about Novo’s strategy, leading to a drop in its stock price after its Capital Markets Day event. The company aims to diversify into new therapeutic areas but has yet to provide clear near-term turnaround plans. Meanwhile, Eli Lilly continues to gain traction across the GLP-1 market, particularly with its obesity pill Foundayo and injection Zepbound. Lilly reported that one-third of new oral GLP-1 patients are using its drug, while it dominates 61% of the U.S. GLP-1 space in Q2 compared to Novo’s 39%. The company is also capturing a significant share of Medicare-covered obesity treatments. Analysts suggest Lilly's commercial strength and early market entry give it an edge over Novo as both compete for leadership in one of the fastest-growing pharmaceutical segments.
Topics: Eli Lilly Foundayo Novo Nordisk obesity drugs Ozempic Wegovy